Logo for Endo International plc

Endo International Investor Relations Material

Latest events

Logo for Endo International plc

Q1 2022

Endo International
Logo for Endo International

Q4 2023

6 Mar, 2024
Logo for Endo International

Q3 2023

6 Nov, 2023
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from Endo International plc

Access all reports
Endo International plc is a specialty pharmaceutical company, principally engaged in the manufacture, development, and marketing of generic and branded pharmaceutical products. Its Branded Pharmaceuticals segment includes the XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urology.